{"disease":{"id":"juvenile-neuronal-ceroid-lipofuscinosis","name":"juvenile neuronal ceroid lipofuscinosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03307304","title":"Investigations of Juvenile Neuronal Ceroid Lipofuscinosis","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT05642221","title":"Functional Near-Infrared Spectroscopy (fNIRS) Combined With Diffuse Correlation Spectroscopy (DCS) in Neurocognitive Disease as Compared to Healthy Neurotypical Controls","phase":"","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT04637282","title":"Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":39,"lead_sponsor_name":"Polaryx Therapeutics, Inc.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}